Featured Articles From The Current Issue
ANTIGEN-SCREENING SYSTEM - Perfecting the Promise of T Cell Therapies for Infectious Disease & Cancer
Jessica B. Flechtner, PhD, explains how the information and insights gleaned from ATLAS, Genocea has been able to successfully define targets of human T cell responses that become central to novel vaccines and immunotherapies, and demonstrate success in a clinical setting.


>>> See All Cover Stories

Jean Pierre Wery, President of Crown Bioscience, discusses the requirement for more accurate research models in oncology research, focusing on PDX models that have the ability to more adequately represent the conditions and mechanisms of immunotherapy in human patients.
John A. Bermingham says it is not a matter of IF your business is going to be hacked but WHEN your business is going to be hacked, but the vast majority of businesses in the US do not have any plans in place for such an event.
Derek Hennecke says once we understand what happens in our brains as we weigh our options, we can extrapolate this knowledge and look with fresh eyes at how CDMOs, large pharma, and the industry make decisions.
Lilli Zakarija, MSME, MBA, cautions that while OTS devices are already “developed” and on the market, they should still go through the device development design control process from the perspective of the combination product, and then let the design control process determine if the device meets the specific requirements of the CP.
Xiaoyi Xu, MS, Chandreyee Das, PhD, and Michael Sturges, PhD, indicate that the phosphorylation of histidine has not been widely studied in mammalian cells, despite its discovery in bovine liver mitochondria, and ask the question, could the phosphorylation of histidine emerge as a therapeutically important pathway in mammals?
T.R. Shantha, MD, PhD, FACA, says the market for new anti-diabetic therapeutic agents and their painless delivery is enormous and is sure drug companies and research scientists are in a race to develop a safer method other than the pulmonary and oral routes to deliver insulin.
Bruce K. Redding, Jr, CEO and Founder of TSI, discusses the importance of developing a new tool for enhanced drug delivery, but also a means to reduce the time-to-market for new formulations while also expanding the number of drugs that can be delivered transdermally.
Enrico Corona, indicates full scalability between laboratory and production lyophilization units allows for the development or optimization of freeze-drying cycle parameters that yield significant cost savings.
John A. Bermingham asks what’s the difference between leadership and management? Or is there one?
Contributor Cindy H. Dubin highlights several CDMOs that are evolving their models to become their clients’ single provider and to accommodate their more potent, challenging products.
Jean Pierre Wery, PhD, indicates immunotherapy in combination with traditional treatments has the potential for becoming a more effective alternative to the current standard of care. These types of combination therapies are currently under investigation and appear to have synergistic effects compared to the use of one therapy alone.
Andrew N. Cleland, PhD, Jean-Luc Fraikin, PhD, Peter Meinhold, PhD, and Franklin Monzon, PhD, describe a new diagnostic instrument able to rapidly and accurately report detailed nanoparticle size distributions for a wide variety of nanoparticle types and concentrations in a range of different solutions.
Exclusive Online Content
The Promise of Stem Cell Research Yields Double-Digit Growth RatesThe Promise of Stem Cell Research Yields Double-Digit Growth Rates
Although products based on stem cells have yet to form an established market, unlike some other potential applications of bioscience, stem cell technology has already produced a number of significant products in important therapeutic areas. BCC Research reveals in its new report that researchers around the world are using stem cells to achieve new outcomes that will mark a paradigm shift in drug discovery and the medicine world.

Technology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 BillionTechnology Advancements in Protein Therapeutics Spurring Market Growth to $248.7 Billion
Protein drugs have gained importance for their therapeutic applications, and the numbers of products have increased in recent years. BCC Research reveals in its new report that novel technologies, such as recombinant DNA (recombinant deoxyribonucleic acid or rDNA) technology and genetic engineering, have lifted the market for protein drugs to new heights.

Ajinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal AntibodiesAjinomoto Althea, Inc. Announces Issuance of New US Patent for Manufacturing of Crystal Monoclonal Antibodies
Ajinomoto Althea Inc., a leading provider of biotherapeutic contract development and manufacturing services, today announced that the United States Patent and Trademark Office has issued US Patent 9,310,379 covering methods to crystallize monoclonal antibodies for the purpose of scale up and cGMP manufacturing for therapeutic use. The patented methods are important for successful stabilization, storage and delivery of biologically active antibody crystals.

Capsugel Expands Micro-Dosing Services to Help Accelerate Customers' Product Development Timelines Capsugel Expands Micro-Dosing Services to Help Accelerate Customers' Product Development Timelines
Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, today announced that it is expanding its micro-dosing services offering for early-phase feasibility work. Capsugel’s offering combines its proprietary Xcelodose® Precision Powder Micro-Dosing Systems with industry-leading powder-in-capsule/powder-in-bottle (PIC/PIB) expertise developed at Xcelience, which Capsugel acquired in January.

Aptar Pharma's Preservative-Free Multi-Dose Ophthalmic Squeeze Dispenser Launched in USAptar Pharma's Preservative-Free Multi-Dose Ophthalmic Squeeze Dispenser Launched in US
Aptar Pharma, a global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, has partnered with a leading eye care company to develop and launch a new eye drop product, which uses Aptar Pharma’s innovative preservative free multi-dose Ophthalmic Squeeze Dispenser (OSD).

Dublin-Based Innopharma Technology Announces Strategic Collaboration With Glatt Dublin-Based Innopharma Technology Announces Strategic Collaboration With Glatt
Dublin-based Innopharma Technology and Glatt (India) Systems Pvt. Ltd. have recently announced a strategic collaboration that is set to reduce product manufacturing costs while increasing compliance and product quality for the pharmaceutical, MedTech, and food industries.

Disease-Modifying Drugs Will Propel Huntington’s Disease Market to $2.6 Billion Disease-Modifying Drugs Will Propel Huntington’s Disease Market to $2.6 Billion
The Huntington’s disease market will rise from around $252.6 million in 2014 to over $2.6 billion in 2024, representing a huge Compound Annual Growth Rate (CAGR) of 25.6%, according to research and consulting firm GlobalData.

Meggle Announces New Head of Sales & MarketingMeggle Announces New Head of Sales & Marketing
The Business Group Excipients & Technology of MEGGLE announced the appointment of Dr. Albrecht Kraemer, as its new Head of Sales & Marketing as of April 1, 2016

Heart Failure Market to Soar to $11.8 Billion by 2025 Heart Failure Market to Soar to $11.8 Billion by 2025
The heart failure market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, representing a compound annual growth rate of 13.7%, according to research and consulting firm GlobalData.

Comparative Human In Vivo Study of an Immediate-Release Tablet Over-Encapsulated by Gelatin & Hydroxypropyl Methyl Cellulose Capsules – Impact of Dissolution Rate on BioequivalenceComparative Human In Vivo Study of an Immediate-Release Tablet Over-Encapsulated by Gelatin & Hydroxypropyl Methyl Cellulose Capsules – Impact of Dissolution Rate on Bioequivalence
Rapid and consistent in-vivo drug dissolution is critical for drug absorption. In-vitro dissolutions tests are used to predict in-vivo disintegration and dissolution properties of drug products...
Market News & Trends




















Click here to see the showcases


AAPS National Biotechnology Conference
May 16-18
Boston, MA

Cleaning Validation Summit
May 23-24, 2016
Racquet Club of Philadelphia, PA

BIO 2016
June 6-9
San Francisco, CA

PharmaPack
June 14-15
New York, NY

Controlled Release Society Meeting
July 17-20
Seattle, WA

Process Validation Summit
June 27-28, 2016
Racquet Club of Philadelphia, PA

Transdermal Drug Delivery Systems
September 12-13, 2016
Racquet Club of Philadelphia, PA

CPhI Worldwide
October 4-6
Barcelona, Spain

PDA – Universe of Pre-filled Syringes & Injection Devices
October 17-18
Huntington Beach, CA

Pharma Ed's Extractables and Leachables Forum
October 24-25, 2016
Racquet Club of Philadelphia

AAPS Annual Meeting
November 13-17
Denver, CO

 



Copyright © 2016  Drug Development & Delivery All Rights Reserved. Privacy Policy / Terms and Conditions